Incretin/ja: Difference between revisions

Some incretins ([[GLP-1]]) also inhibit [[glucagon]] release from the [[alpha cell]]s of the [[islets of Langerhans]]. In addition, they slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. The two main candidate peptides that fulfill criteria for an incretin are the intestinal [[peptide]]s [[glucagon-like peptide-1]] (GLP-1) and [[gastric inhibitory peptide]] (GIP, also known as: glucose-dependent insulinotropic polypeptide). GIP is produced and secreted into the blood circulation by [[Enteroendocrine cell#K cell|K cells]], i.e., single cells located in the mucosa of the [[upper gastrointestinal tract]]'s [[duodenum]] and upper [[jejunum]] while GLP1 is produced and secreted into the blood by [[Enteroendocrine cell#L cell|L cells]] located in the mucosa of the [[lower gastrointestinal tract]]s [[small intestine|small]] and [[large intestine]]s. [[Short-chain fatty acids]] (primarily [[acetic acid|acetic]], [[propionic acid|propionic]], and [[butyric acid]]s), which [[Microbiota|microganisms]] form in the intestines, bind to the [[FFAR2]] and [[FFAR3]] receptors on K cells and L cells to stimulate their respective production and secretion of GIP and GLP-1. Both GLP-1 and GIP are rapidly inactivated by the enzyme [[dipeptidyl peptidase-4]] (DPP-4) and are members of the glucagon peptide superfamily.